RPG Life Sciences Ltd Q1 FY2027 Concall Summary

Key Takeaways

• API business transformed overnight: Two acquisitions plus a PE partnership turned a ~110 kg single-site operation into a 505 kg, multi-site, backward-integrated platform with 45+ products and 250+ customers, without major additional capex.
• ₹700 crore war chest for API roll-up: Management earmarked ₹700 crore for further API acquisitions and capacity, targeting deployment within 12–15 months, with both RPG and InvaSant committed to fund opportunities as they arise.
• Formulation engine gets undivided attention: The API carve-out into RPG Active Pharma frees management bandwidth for the domestic formulation business, which has been growing 1.3–1.8x the market and now gets a dedicated leadership team, new therapy launches, and a strengthened marketing engine.
• Actors decline was a capacity story, not a demand problem: Revenue fell from ₹70 cr to ₹48 cr on price erosion in one intermediate while the facility ran full; the acquired Raghava capacity now provides the headroom to restore and grow that revenue stream.
• What to watch next quarter: Closing and integration of the Actis and Raghava acquisitions, any further API M&A deployment from the ₹700 crore fund, and whether the formulation business sustains its market-beating trajectory with the new dedicated focus.

The API Platform Build

• Scale transformation in months: The API business moved from a standalone operation with ~110 kg capacity, 217 people, 28 R&D scientists, 14 products, 123 customers, and 12 pipeline molecules to a multi-site organization with ~505 kg capacity, 500+ professionals, 53 R&D scientists, 45+ products, 250+ customers, and 28 pipeline molecules, achieved without major additional capex.
• Three-part structure: RPG Life Sciences transferred its existing API business into subsidiary RPG Active Pharma, brought in healthcare-focused PE investor InvaSant for a 40% fully diluted stake, then announced the acquisitions of Actis Generics (~₹80 cr including net working capital) and Raghava Life Sciences' API and intermediate business (up to ₹135 cr including net working capital).
• Raghava brings instant capacity and approvals: The acquired facility near Hyderabad holds WHO GMP and EU GMP approvals, has seen significant recent investment with modern infrastructure, and carries 29 molecules (22 commercialized, 7 development-stage) with established marquee customer relationships. Management sees meaningful headroom for growth within the existing asset base, with immediate focus on improving utilization, strengthening commercialization, and optimizing product mix rather than large capex.
• Actis adds backward integration: Actis Generics is a fully backward-integrated platform for APIs and complex intermediates, operating close to full capacity, which complements the existing API portfolio and Raghava's forward capabilities.
• Actors capacity constraint resolved: The legacy Actors business declined from ₹70 cr to ₹48 cr solely because of price erosion in one key intermediate while the facility ran at full capacity, not due to structural issues. The acquired Raghava capacity now allows the company to utilize available capacity in other group companies to ramp up revenue where Actors has demand but was previously constrained.
• Dedicated leadership installed: Deepak Shukla appointed as CEO of the API business with deep industry experience, a leadership team is being built, and a top consulting firm has been engaged to support post-acquisition integration with a disciplined PMO running across all workstreams.

Nair: "We believe that by combining Ragwa's product and capacity with AKPI's backward integration possibilities, RPG's existing API business systems, processes and governance framework along with our PE partner sector expertise, we can unlock substantially more value than either asset could achieve independently."

API Growth Ambition & Capital Deployment

• 25%+ growth CAGR targeted: Management is targeting superlative 25% plus growth CAGR in the API business through organic and inorganic interventions, sustaining over the next five years. On a consolidated basis, the enduring target is 20%+ CAGR over the next three to four years.
• ₹1,000 crore aspiration: The path to ₹1,000 crore in the API business is expected in five to six years through collective organic and inorganic initiatives; the company is currently at almost halfway to that benchmark after the two acquisitions. The next milestone is crossing ₹200 cr revenue in approximately another two years.
• ₹700 crore earmarked for M&A and capacity: The ₹700 crore fund is allocated for API business acquisitions, with some portion for capacity building and improving R&D capabilities. Deployment is expected over the next 12 to 15 months, with an endeavor to deploy within the next 12 months.
• Acquisition lens is building-block, not portfolio: Every API acquisition will be evaluated as a building block in one integrated company focused on deep capabilities, capacity, chemistry, product portfolio, approvals, and customers. The focus remains on niche APIs that are multi-step, complex chemistry, and low price erosion, in therapies such as nephrology and other chronic segments.
• US market access on the roadmap: Management will look to incorporate US FDA approvals and therefore access to US markets as part of the larger strategy. Raghava's existing international approvals and products are strong, and with synergy, customer know-how, and cross-selling, the company expects to take Raghava molecules to international markets.
• Valuation discipline claimed: Acquisitions are and will remain at prudent valuations with organic sales growth and margin improvement; management expects large upside from multiple expansion. The focus on niche, difficult-to-make molecules means valuation multiples are expected on the higher side of the spectrum versus commodity contracts.
• Capital commitment from both partners: Both RPG and InvaSant will keep investing as opportunities arise, aligned around long-term growth. Management declined to provide the specific split of the ₹700 crore between the two parties, stating only that both will invest considering the shareholding pattern.

Nair: "We have been very clear that our play has to be niche molecules. Our play has to be in molecules which is difficult to make and where you need multiple step synthesis and multiple step development."

Domestic Formulation: The Other Engine

• Market-beating growth track record: The domestic formulation business has delivered market-beating growth consistently over the last five quarters, growing 1.3 to 1.8 times the market, helping RPG Life Sciences enter the top 50 pharma company list and become the fifth fastest growing pharma company in India in the last quarter.
• API carve-out frees management bandwidth: The API business transfer into RPG Active Pharma increases management bandwidth for the formulation engine, with a separate dedicated management team now running the API vertical. The formulation business has separate, increased focus, and management strongly believes domestic formulation should further grow from current levels.
• Organizational strengthening underway: New talent has been brought in to head the domestic formulation business, the business has been further segmented into super-specialty businesses, a new business division has been launched in cardiology and urology, and the marketing and digital team has been strengthened.
• Growth target: The formulation business aims to grow 1.5x the market, with the expectation that domestic formulation should further grow from current levels with the increased focus now that API has dedicated leadership.

Nair: "We in fact strengthened our whole marketing the digital team in the business domestic continues and in fact has an increased focus since now API has got a dedicated for focus. In fact we strongly believe that domestic formulation should further grow from what we are doing today."

Margin & Synergy Expectations

• API margin target in mid-20s: Management disclosed that API margins are in the mid-20s and will be at a similar line with the acquisitions, though there will be pressure in the initial period post-acquisition before returning to that range. The company declined to provide current EBITDA margin levels for Raghava or the API business.
• Synergy levers identified: Opportunities have been identified across backward integration, manufacturing optimization, capacity utilization, and customer expansion to improve competitiveness. Synergies are expected to drive higher growth, better margins, and stronger returns on capital deployment over time.
• Raghava value unlock plan: Strengthening business development, increasing utilization, expanding into higher-value markets (especially EU-focused), optimizing product costs, and creating better operating leverage are the stated levers.
• No major capex needed for growth: The Raghava facility has already seen significant investment in recent years with modern infrastructure, regulatory approvals, and substantial instant capacity. The immediate focus is not large capex but improving utilization, strengthening commercialization, optimizing product mix, and driving operational efficiencies.

Structure & Governance

• RPG Active Pharma board: The long-term strategic partner InvaSant will have representation on the RPG Active Pharma board, contributing governance, sector expertise, and strategic guidance. Raghava and Actors will not have any board role.
• 40% stake reflects in consolidated financials: InvaSant's 40% shareholding in RPG Active Pharma will reflect in consolidated financials from Q1 FY27.
• Valuation questions unanswered: When asked about the apparent discrepancy between InvaSant's investment (~₹600 crore valuation for 40% stake) and the rights issue (~₹210 crore valuation), management stated the two activities are completely different, with subsidiarization happening first, then the investor coming with infusion of money, then acquisitions, but did not directly explain the valuation gap or any arrangement.
• Separate API financials not disclosed: Management declined to provide separate API business numbers including sales, EBITDA, PAT, net worth, fixed assets, or working capital on a trailing or forward basis, stating they are not publishing them as of now.

Guidance & Commitments

Key Metrics